Sanofi SA (NYSE:SNY) shares rose 5.5% during mid-day trading on Friday . The company traded as high as $44.73 and last traded at $44.21. Approximately 4,716,382 shares changed hands during mid-day trading, an increase of 348% from the average daily volume of 1,052,975 shares. The stock had previously closed at $41.91.
SNY has been the topic of a number of research reports. TheStreet lowered shares of Sanofi from a “b” rating to a “c+” rating in a research note on Thursday, February 7th. HC Wainwright reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, February 28th. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $51.00.
The company has a market capitalization of $111.46 billion, a price-to-earnings ratio of 14.12, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.
Hedge funds have recently added to or reduced their stakes in the stock. Essex Savings Bank acquired a new stake in Sanofi during the fourth quarter valued at $30,000. Claybrook Capital LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at about $31,000. Executive Wealth Management LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at about $34,000. Nkcfo LLC acquired a new stake in shares of Sanofi in the first quarter valued at about $35,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Sanofi in the first quarter valued at about $35,000. Institutional investors own 7.04% of the company’s stock.
About Sanofi (NYSE:SNY)
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: How is inflation measured?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.